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B cell development is a multistep process that is tightly regulated at the transcriptional level. In recent years, investigators have
shed light on the transcription factor networks involved in all the differentiation steps comprising B lymphopoiesis. The interplay
between transcription factors and the epigenetic machinery involved in establishing the correct genomic landscape characteristic
of each cellular state is beginning to be dissected. The participation of “epigenetic regulator-transcription factor” complexes is
also crucial for directing cells during reprogramming into pluripotency or lineage conversion. In this context, greater knowledge
of epigenetic regulation during B cell development, transdifferentiation, and reprogramming will enable us to understand better
how epigenetics can control cell lineage commitment and identity. Herein, we review the current knowledge about the epigenetic
events that contribute to B cell development and reprogramming.
1. Introduction
Hematopoietic stem cells (HSCs) give rise to mature B cells
through the sequential differentiation of lymphoid pro-
genitor cells. Long-term HSCs (LT-HSCs) have the ability
to self-renew and reconstitute the entire immune system
by differentiating into short-term HSCs (ST-HSCs). ST-
HSCs differentiate into multipotent progenitors (MPPs) that
then branch into common myeloid progenitors (CMPs)
and lymphoid-primed multipotent progenitors (LMPPs).
CMPs further differentiate into erythrocytes and megakary-
ocytes, whereas LMPPs retain the capability to give rise to
myelomonocytic or lymphoid lineages [1, 2]. LMPPs become
common lymphoid progenitors (CLPs) [3], which have the
potential to differentiate into B and T lymphocytes as well
as natural killer (NK) cells [4, 5]. Once committed to the
lymphoid lineage, further differentiation steps lead to the
formation of pro-B and pre-B cells, which are the early B cell
precursors for immature B cells, the terminally differentiated
plasma cells and germinal-center B cells (Figure 1).
Every step in B cell development is characterized by the
activation of the specific genetic program characteristic of
the new intermediate/progenitor generated and the repres-
sion/extinction of the genetic program of the previous
cellular state. To achieve this, the different differentiation
steps are tightly regulated at the transcriptional level. In
recent years, the theory of the existence of networks of
lineage-specific and identity-transcription factors responsi-
ble for establishing particular genomic landscapes has gained
credence [6]. In the case of lymphocyte development, the
transcription factors Ikaros and PU.1 are critical for the
cellular commitment of LMPPs to the lymphoid lineage
[2]. Subsequently, early B cell specification depends on the
action of E2A, EBF, and FOXO1, whereas Pax5 is required
for proper B cell development and for maintaining B cell
identity [7–12]. Finally, during later developmental stages,
the transcriptional repressors Bcl6 and Blimp-1 are crucial
for the generation of germinal-center B cells and plasma cells,
respectively [13–17] (Figure 1).
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Figure 1: Scheme for B cell development. Successive stages of B cell differentiation and the key transcription factors and epigenetic regulators
involved are shown. The epigenetic regulators that cooperate with specific transcription factors at every cell differentiation step are in purple.
MicroRNA transcript targets are in green.
The picture of the hierarchical network of transcription
factors that mediate the epigenetic signature needed to
regulate the specific transcriptome of the fate of B-cells
during their development has begun to emerge [18–20]. For
example, Pax5, whose expression is induced by E2A and
EBF, recruits chromatin-remodeling, histone-modifying and
transcription-factor complexes to its target genes to activate
the transcription of B cell-specific genes, and to silence
lineage-inappropriate genes [19]. Extensive efforts have been
made to elucidate the epigenetic mechanisms underlying
the gene rearrangements of various components of the B
cell receptor (BCR) [21–23]. Thus, epigenetic regulation
is a critical event in B lymphocyte development. The
relevance of transcription factors to the establishment and
maintenance of cell-lineage identity has also been demon-
strated in cellular reprogramming experiments [24–27]. The
epigenetic mechanisms involved in the reprogramming and
transdifferentiation of B cells have also been a focus of study
in recent years.
Nucleosomes are the basic unit of the chromatin. They
comprise 147 bp of DNA wrapped around a histone core,
which contains two copies each of H2A, H2B, H3, and
H4. This core is important for establishing interactions
between nucleosomes and within the nucleosome itself
[28]. Depending on the epigenetic modifications on the
histone tails and in the DNA, chromatin can adopt different
structural conformations that are correlated with its active,
permissive (primed), or repressive status. The four main
mechanisms by which epigenetic regulation occurs are DNA
methylation, histone modification, chromatin remodeling,
and regulation of gene expression by the action of noncoding
RNAs. The methylation of cytosine residues at CpG dinu-
cleotides (methyl-CpG), which is generally associated with
transcriptional repression, is accomplished via the action
of DNA methyltransferases (DNMTs) [29]. Methyl-CpG-
mediated transcriptional repression can be explained by
two nonmutually exclusive molecular mechanisms. First,
methylation of DNA can interfere with the accessibility and
recruitment of transcription factors to their DNA-binding
sites. Second, DNA methylation results in the recruitment of
methyl-CpG-binding proteins (MeCPs and MBDs) in asso-
ciation with corepressor complexes. Both mechanisms lead
to the transcriptional silencing of the methylated genes [29].
The posttranslational modification of histones is another
important epigenetic regulatory mechanism. Histones can
be posttranslationally modified by a variety of enzymatic
modifications, including acetylation, methylation, phospho-
rylation, sumoylation, and ubiquitination among others
[30]. While acetylation is generally considered to be a mark
of transcriptional activation, histone methylation can result
in either transcriptional activation or repression, depending
on the residue that is modified. In this regard, acetylation of
histone H3 on lysine 9, 14, and or 18 (H3K9ac, H3K14ac,
H3K18ac) is associated with transcriptional activation and
considered “histone active marks.” In the case of histone
methylation, di- and tri-methylation of histone H3 at lysine
4 (H3K4me2, H3K4me3) are associated with transcriptional
activation and therefore considered an active mark, whereas
trimethylation of H3 at lysine 27 (H3K27me3) is found to be
enriched at silenced genes and considered to be a repressive
histone mark [28, 30]. Trimethylation of histone H3 at lysine
9 (H3K9me3) has also been characterized as a mark of
transcriptional repression [30]. However, different reports
suggest that it can also represent transcriptional activity [31,
32]. Another mechanism of epigenetic regulation involves
the action of chromatin remodelers, which are multi-subunit
complexes that use the energy from ATP hydrolysis to change
the location or conformation of nucleosomes, resulting in
increased or decreased DNA accessibility [28]. Chromatin-
remodeling complexes can be divided into four groups,
characterized by core ATPase subunits. Based on the defining
ATPase, they are referred to as the SWI/SNF, ISWI, CHD,
and INO80 families of remodelers [28]. Finally, microRNAs
(miRNAs), a type of small noncoding RNAs, have been
shown to anneal to 3′UTR of cognate mRNAs, leading
to mRNA instability and/or the inhibition of translation,
thereby making it possible to modulate the proteome of the
cell [29].
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In this papre we will summarize the recent advances in
our understanding of the epigenetic mechanisms controlling
B cell development and reprogramming.
2. B Cell Development: Early Specification
towards the Lymphoid Lineage
When cells are at the LMPP stage, two transcription factors,
Ikaros and PU.1, play critical roles in the early cellular spec-
ification towards the lymphoid lineage. Mice homozygous
for a germline mutation in the Ikaros DNA-binding domain
present a block at early lymphocyte development and
therefore lack lymphocyte progenitors, T and B lymphocytes,
as well as natural killer cells [33, 34]. More recently, Ikaros
was shown to be a crucial transcription factor for the
commitment of LMPPs into CLPs, clearly demonstrating its
key role in the early cellular decision to undergo lymphocyte
development [2]. LMPPs derived from Ikaros-null mice lack
B cell potential and do not express Flt3, Il-7r, Rag1 and
Rag2, which are important genes for lymphoid commitment
[2]. Mechanistically, Ikaros can either activate or repress
transcription of target genes, depending on the recruitment
of coactivators or corepressors. For example, in T cells,
Ikaros has been shown to recruit corepressor or chromatin
remodeling complexes in order to either repress or activate
specific targets [35–37]. However, how Ikaros mediates
the epigenetic regulation of its target genes during the
differentiation of LMPPs into CLPs remains to be elucidated.
Likewise, the transcription factor PU.1 is crucial for the
commitment of LMPPs to the lymphoid lineage. Strikingly,
PU.1 is also required for the generation of GMPs and
macrophages. In fact, mice deficient for PU.1 die around
birth and lack B, T, NK and myelomonocytic cells [38, 39].
The promiscuity of PU.1 in regulating gene expression in
different cell types raised the general question of what the
mechanism of action is of a given transcription factor in
different cell types. In this regard, Heinz et al. recently
identified the genomewide binding sites of PU.1 in splenic B
cells, macrophages and B cell progenitors [40]. They found
that PU.1 cooperates with cell-type-specific transcription
factors to activate the cisregulatory elements required for
the development of a particular cell type. For example, in
CLPs and pro-B cells, E2A induces PU.1 binding at B cell-
specific genomic sites that contain closely located PU.1 and
E2A binding motifs [40]. In addition, PU.1 binding initiates
nucleosome remodeling, followed by H3K4me enrichment at
many specific genomic regions [40]. These data could lead us
to speculate that cooperation between PU.1 and Ikaros might
be crucial for the activation of specific genes required to
specify LMPP into CLPs. Also, the identity of Ikaros and PU.1
epigenetic partners remains unknown. This matter awaits
investigation.
3. B Cell Development: Early
B Cell Commitment
B cell development is characterized by the generation of the
BCR, which consists of a heavy and a light immunoglobulin
chain, IgH and IgL, respectively. The expression of the BCR
subunits VpreB, λ5, and mb-1 (Cd79a), and the initiation
of D-J rearrangements at the IgH locus defines early B cell
commitment [41]. The specification of CLPs in the B cell
lineage requires two transcription factors, E2A and EBF1,
which have been shown to activate the expression of genes
essential for the formation of pro-B cells [42]. E2A and
EBF knockout mouse models are phenotypically similar,
and both transcription factors are considered to play key
roles in initiating B lymphopoiesis. E2A-deficient mice show
arrested B cell development at the pre-pro-B cell stage with
compromised D-J rearrangements at the IgH locus and a lack
of expression of Rag1, mb-1, Iν, λ5, Cd19, and Pax5 genes
[7–9]. More recently, it was shown that conditional deletion
of E2A in pre-B cells did not result in a complete loss of
expression of its target genes, indicating the involvement of
E2A in the early steps of B cell commitment [43]. Similar to
E2A, EBF is also known to play a crucial role in initiating
B cell development. Mice lacking EBF do not express Rag1,
Rag2, mb-1, B29 (Igβ), λ5, VpreB, cd19, or Pax5 genes [10].
Recent studies have also implicated the transcription factor
FOXO-1 in early B lymphopoiesis. FOXO-1-deficient mice
also show a developmental block at the pro-B cell stage [11].
Moreover, it has been reported that FOXO-1 regulates Rag1
and Rag2 expression [44].
Recent evidence indicates that the network of tran-
scription factors Pax5, E2A and EBF also cooperate to
regulate their target genes. For example, E2A, EBF, and Pax5
coordinate epigenetic events that lead to the expression of
mb-1, which encodes the Igα subunit of the pre-BCR and
BCR [45]. mb-1 is methylated at CpG dinucleotides in HSCs
and is gradually demethylated during B cell commitment
correlating with its pattern of expression [21]. EBF and
E2A contribute to the CpG demethylation and nucleosomal
remodeling of the mb-1 promoter, an event necessary
for its transcriptional activation by Pax5. ATP-dependent
chromatin remodeling complexes have also been implicated
in EBF and Pax5-mediated regulation of the mb-1 gene
[21]. Knockdown of Brg1 and Brm, the catalytic subunits
of the SWI/SNF chromatin-remodeling complex interfere
with EBF and Pax5-mediated activation of mb-1. In contrast,
knockdown of Mi-2, the catalytic subunit of the Mi-2/NuRD
chromatin-remodeling complex, enhances chromatin acces-
sibility and demethylation of the mb-1 promoter and its
transcription in response to both transcription factors [21].
These results are consistent with a model in which the
SWI/SNF and Mi-2/NuRD chromatin remodeling complexes
play antagonistic regulatory roles to enable or limit the
reprogramming of target genes by EBF and Pax5 during
B cell development [21]. The B-cell-specific gene Cd19 is
another example of a gene that is epigenetically regulated
during early B cell development. Cd19 encodes a cell surface
protein that participates in signal transduction mechanisms
via the BCR and pre-BCR. Chromatin remodeling at the
upstream enhancer sequences of Cd19 occurs in multipotent
progenitors [22]. This chromatin remodeling has been
shown to facilitate the recruitment of E2A to this locus
followed by EBF and Pax5 recruitment [22]. Interestingly, the
Cd19 promoter is transcriptionally activated only after Pax5
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binding. In this context, Mercer et al. recently reported that
the monomethylation of H3K4 (H3K4me) at the enhancer
regions of cell lineage-specifying genes is the main epigenetic
mark, which is associated with their specific expression
pattern throughout the lymphoid differentiation program
[46]. Taken together, these reports provide clear examples of
how B cell lineage-specific transcription factors cooperatively
mediate the epigenetic regulation of target genes during B
lymphopoiesis.
The recent advances in ultrasequencing technologies are
helping to draw a global picture of how the networks of
transcription factors modify the chromatin of their target
genes. The laboratory of Cornelis Murre, using a ChIP-seq
experimental approach, has elucidated how the network of
transcription factors E2A, EBF and FOXO-1 orchestrates B
cell commitment [18]. They found that during the transition
of pre-pro-B cell to pro-B cells, E2A-associated genes become
monomethylated at lysine 4 on H3 (H3K4me), a mark
mainly found on gene enhancer elements. Subsequently, EBF
and FOXO1 are involved in the enrichment of active histone
modifications such as H3K4me3 on B-cell-specifying genes,
such as Pax5 [18]. Recently, Treiber and colleagues have
shed light on the EBF-mediated epigenetic regulation of its
target genes [47]. They classified EBF targets as activated,
repressed, or primed genes. They observed that, in pro-B and
pre-B cells, the “activated” genes are enriched in H3K4me3
and H3 acetylation active marks and show low levels of the
repressive mark H3K27me3 [47]. In contrast, the “repressed”
genes show the opposite pattern of histone modifications.
The “primed” genes are enriched in the gene enhancer mark
H3K4me in pre-B and pro-B cells and enriched in H3K4me3
and H3 acetylation in mature B cells [47]. The identification
of the epigenetic regulators recruited by transcription factors
to mediate gene expression changes during B lymphopoiesis
remains to be addressed.
Other epigenetic marks, such as ubiquitination of His-
tone H2A, have proved to play a role in early B cell
development. Jiang et al. pointed out that the histone H2A
deubiquitinase MYSM1 is an important factor in B cell devel-
opment [48]. Mysm1 knockout mice show a drastic decrease
in the number of B cells in the bone marrow, peripheral
blood, and lymph nodes [48]. The authors concluded that
MYSM1 antagonizes the action of the polycomb repressive
complex 1 (PRC1) on the Ebf1 promoter, enabling lineage-
specific transcription factors, such as E2A, to be recruited to
the Ebf1 locus and to induce its transcription [48].
Early B cell development is also known to be regulated
by microRNAs. Mice deficient in Ago2, which encodes a
protein essential for microRNA biogenesis and function,
display a block in B cell development at the pro-B cell stage
[49]. Consistent with this, specific deletion of Dicer in pro-
B cells, which abolishes the entire miRNA network in B
cells, results in a complete block of B cell differentiation
at the transition from pro-B to pre-B-cells [50]. Another
study reported that miR-181, one of the approximately 100
microRNAs known to be expressed in mouse bone marrow
cells, is more abundant in the B cell lineage than in other cell
types [51]. Transplantation of multipotent hematopoietic
progenitors overexpressing miR-181 into lethally irradiated
mice resulted in an increase in the number of B cells [51].
Thus, miR-181 appears to target and repress the transcripts
of critical genes involved in generating B cells. A similar
experimental approach was used to show that another
microRNA, miR-150, which is expressed in mature B and
T cells, can block B cell differentiation at the pro-B cell
stage when expressed prematurely [52]. Accordingly, the
laboratory of Klaus Rajewsky reported that miR-150 plays
a role during B cell differentiation through its action on c-
Myb expression [53]. Other miRNAs have been associated
with the early development of B cells. For instance, miR-
34a ablation results in a developmental block at the pre-
B cell stage, and miR-17-92 knockout mice exhibit a block
in pro-B cells [54, 55]. They regulate the Foxbp1 and Bim
and PTEN genes, respectively, which are known to have a
role in B cell differentiation [54, 55]. Recently, Kuchen et
al. have elucidated the microRNAome during lymphopoiesis
at the genome-wide scale, leading to the identification of
miRNAs that are primed for expression at different stages of
differentiation [56]. They reported that miRNA expression is
tightly regulated by epigenetic modifications. In particular,
they showed that the repressive mark H3K27me3 is associ-
ated with the gene silencing of lineage-inappropriate miRNA
during lymphopoiesis [56]. However, they also observed that
active epigenetic regulation by the presence of H3K4me also
occurs in some of the microRNAs “primed” to be expressed.
On the basis of the restrictive expression and abundance of
miRNAs during B cell lineage specification, miR-320, miR-
191, miR-139 and miR28 appear to be potential regulators
of B cell differentiation [56]. The transcripts targeted by key
miRNAs for the early differentiation of B cells remains to be
identified.
4. B Cell Development: Pax5 in the Maintenance
of B Cell Identity
The transcription factor Pax5 is essential for maintaining the
fate of B cells and is therefore considered to be “the guardian
of B cell identity” [57]. Its expression gradually increases in a
stepwise manner during B cell development. Pax5 expression
is first detected at the early pro-B cell stage and maintained
up to the mature B cell stage. Pax5 knockout mice show
a block in B cell development at the pro-B stage [12].
Pax5−/− pro-B cells express both E2A and EBF transcription
factors, as well as their target genes. In contrast, E2A−/−
and EBF−/− derived cells do not express Pax5. Collectively,
these data indicate that Pax5 is a target for both transcription,
factors. The laboratory of Meinrad Busslinger has shed
light on the molecular mechanisms involved in the gradual
expression of Pax5 during B cell development. In particular,
they have identified an enhancer in the Pax5 locus, which in
combination with the promoter, recapitulates B lymphoid
Pax5 expression [58]. Interestingly, the Pax5 enhancer is
silenced by DNA methylation in embryonic stem cells,
while it becomes activated in multipotent hematopoietic
progenitors. The presence of consensus binding sites for the
transcription factors PU.1, IRF4, IRF8, and NF-k B within
the Pax5 enhancer suggests that these transcription factors
play a role in sequential enhancer activation in hematopoietic
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progenitors and during B cell development [58]. At the onset
of pro-B cell development the transcription factor EBF1
induces chromatin remodeling at the Pax5 promoter region.
In non-B cells, Polycomb group proteins repress the Pax5
promoter region [58].
In addition to the epigenetic regulation of its expression
during B cell development, Pax5 induces the establishment
of a B cell-specific transcription program that is associated
with the suppression of inappropriate genes of alternative
lineages, thereby ensuring its role in maintaining B cell iden-
tity and differentiation. Using gene expression microarrays
and genome-wide ChIP-on-chip experimental approaches,
the laboratories of Busslinger and Nutt have described the
complex gene regulatory network regulated by Pax5 during
B lymphopoiesis [59–61]. These studies have identified genes
that are activated or repressed by Pax5 in wildtype pro-
B cells. Pax5-activated genes appear to encode transcrip-
tion factors and key proteins involved in B cell signaling,
adhesion, migration, antigen presentation and germinal-
center B cell formation [59, 61]. However, Pax5-repressed
genes encode secrete proteins, cell adhesion molecules,
signal transducers and nuclear proteins that are specific
to erythroid, myeloid, and T cell lineages [59, 61]. Pax5-
activated genes in pro-B cells were found to be enriched with
epigenetically active marks, including H3K9ac, H3K4me2
and H3K4me3 [60]. Importantly, in Pax5-deficient pro-B
cells, these active histone marks were dramatically reduced
or lost, indicating that Pax5 is essential for guaranteeing
the active chromatin structure at its target genes. These
findings demonstrate that Pax5 is a master regulator of B
cell identity, which, in conjunction with epigenetic regula-
tors, coordinates a B-cell-specific target gene transcription
program. Recently, McManus and colleagues have described
the epigenetic mechanisms mediated by Pax5 during B
lymphopoiesis [19]. By using a ChIP-on-chip analysis, they
have identified Pax5 target genes in committed pro-B cells.
The authors also apply a proteomic approach to identify Pax5
interacting partners. They found that Pax5 interacts with the
members of the SWI/SNF chromatin remodeling complex
Brg1. BAF57 and BAF170. They also reported that PAX5
recruits the NCoR1 repressor complex with its associated
HDAC3 activity to repressed its target genes [19]. This study
has provided novel important insight into the regulatory
network and epigenetic regulation, by which Pax5 directly
controls B-cell commitment at the onset of B lymphopoiesis.
The mechanism by which Pax5 mediates transcriptional
repression of targets has also been informatively examined
using a candidate gene approach. One of the important target
genes repressed by Pax5 in B cells is the colony-stimulating
factor receptor 1 gene (csf1r or c-fms), a gene essential for
macrophage development. Csf1r is expressed at low levels in
HSCs and downregulated in all nonmacrophage cell types.
In HSCs, MPPs, CMPs, and CLPs the Csf1r promoter is
bound by transcription factors and its chromatin structure
in an active conformation [62]. However, the Csf1r gene
is silenced during B cell differentiation. Interestingly, an
intronic antisense transcription unit that is differentially
regulated during lymphopoiesis overlaps with regions of
de novo DNA methylation in B cells, highlighting DNA
methylation as a mechanism for Csf1r silencing during B
cell development. Despite being silenced, Csf1r chromatin
remains in a poised or primed conformation even in mature
B cell stages. Importantly, Csf1r expression can be reactivated
by conditional deletion of the transcription factor Pax5 [62].
Pax5 was shown to bind the Csf1r gene directly, resulting
in loss of RNA polymerase II recruitment and binding of
myeloid transcription factors at cisregulatory elements [63].
Finally, Pax5 in conjunction with linker histone H1 also
coordinates DNA methylation and histone modifications in
the 3′ regulatory region of the immunoglobulin heavy chain
locus and thus epigenetically regulates the IgH locus [64].
5. B Cell Development: Terminal
Differentiation
The completion of V(D)J recombination and expression of
the BCR on the surface of B cells marks the beginning of
antigen-dependent B cell development. From this point, B
cells undergo terminal differentiation dependent on signals
emanating from the BCR after antigen triggering [65].
Peripheral B cells, without antigen-mediated signaling, are
in a resting state [66]. Once activated, they either initiate the
germinal center (GC) reaction or differentiate into antibody-
secreting plasma cells. Entry into the GC reaction is regulated
by Bcl6, whereas the generation of antibody-secreting plasma
cells is controlled by Blimp-1. Bcl6 and Blimp-1 both act as
transcriptional repressors and work in a mutually exclusive
manner [67, 68].
After antigen triggering, Bcl6 is upregulated in some B
cells that then enter the GC reaction [13–15]. In contrast,
cells in which Bcl6 is not upregulated undergo differentiation
into plasma cells [69, 70]. From a mechanistic angle, Bcl6
has been shown to interact with the chromatin remodeling
complex Mi-2/NuRD in GC B cells, leading to the repression
of specific genes that are characteristic of plasma cells
[71, 72]. This Mi-2/NURD-mediated repression requires the
recruitment of histone deacetylases HDAC1 and HDAC2
[71, 72].
After activation of GC B cells Bcl-6 expression is down-
regulated in association with the expression of its target gene
Blimp-1. Once expressed, Blimp-1 represses the gene expres-
sion program of mature B cells, thereby promoting plasma
cell differentiation [16, 17]. Mechanistically, Blimp-1 exerts
its repressive transcriptional activity by recruiting regulators
and coordinating epigenetic modifications at its target genes.
PRD1-BF1, the human orthologue of Blimp-1, silences
the interferon beta gene in response to viral infection by
recruiting the histone methyltransferase (HMTase) G9a to
the interferon-beta promoter, resulting in H3K9me [73].
Blimp-1 has also been found in a complex with the arginine
histone methyl transferase Prmt5, although the functional
significance of this interaction in B cells is not clear [74].
The histone lysine demethylase LSD1 has also been shown to
interact with Blimp-1 [75]. Chromatin immunoprecipitation
(ChIP) experiments indicated that Blimp-1 and LSD1 share
some target genes leading to a more accessible chromatin
structure [75]. Importantly, disruption of the Blimp-1-LSD1
interaction resulted in attenuated antibody secretion of the
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cells, highlighting the functional relevance of this interaction
for B cell function.
In the last few years, additional transcription factors have
emerged as being involved in B cell terminal differentiation.
It has been reported that IRF4 and XBp1 control the mainte-
nance of plasma cell identity. IRF4 is responsible for BLIMP-
1 induction and, in conjunction with XBp1, determines
the fate of the plasma cell. The network of transcription
factors Pax5, Bach2, and Bcl6 direct B cell development
into germinal center cells. It has been shown that Pax5
induces Bach2 expression after B cell activation, which in
turn cooperates with Blc6 to repress Blimp-1 expression
promoting activation-induced cytidine deaminase (AID)
expression and antibody class switch [76, 77].
MicroRNAs are also involved in the terminal differ-
entiation of B cells. Peripheral B cells in transit to their
final maturation can give rise to two functionally distinct
peripheral populations: follicular (FO) or marginal zone
(MZ) B cells. FO versus MZ fate decision is functionally
coupled to BCR signaling and it has been suggested that
B cells bearing BCRs with autoreactive specificities are
preferentially driven into a MZ fate [78]. In 2010, Belver and
colleagues generated conditional Dicer-deficient mice at later
stages of B cell development [79]. They observed that miRNA
metabolism is important for such developmental stage since
these mice presented an impairment in the generation of
follicular B cells and an overrepresentation of marginal zone
B cells. Accordingly, another phenotypic feature of these mice
was the presence of high titers of autoreactive antibodies
[79]. They identified miR185 as an important factor for the
correct BCR-mediated development of B cells.
6. B Cell Reprogramming and
Transdifferentiation
Since 1987, when the possibility of reprogramming spe-
cialized cells by the expression of a linage-specific tran-
scription factor was first reported, many studies have tried
to understand the molecular mechanisms that control all
the processes involved. Due to the high developmental
complexity that characterizes the hematopoietic system, it
constitutes a model system with which study cell reprogram-
ming and transdifferentiation in greater depth. In 1995, it
was reported that overexpression of the erythroid lineage-
specific transcription factor GATA-1 in myeloid leukemia
cells induced their reprogramming into the megakary-
ocytic/erythroid lineage [24]. Subsequently, Nutt et al.
reported that Pax5-defective pro-B cells differentiated into
functional macrophages, granulocytes, natural killer cells,
osteoclasts, and dendritic cells when specific cytokines were
added to the culture medium [26]. Some years later, using
knock-in and lineage-tracing technologies in mice, Xie
and colleagues were able to demonstrate in vivo repro-
gramming of intrasplenic mature B cells into macrophages
by the overexpression of the myeloid transcription factor
C/EBPα [80]. More recently, the same laboratory generated
a robust reprogramming system in which murine pre-
































(b) Reprograming to pluripotency
Figure 2: Transdifferentiation and reprogramming of B cells.
(a) Ectopic expression of C/EBP in pre-B cells induces their
transdifferentiation into macrophages. Epigenetic changes during
the process are shown. (b) B cells can be reprogrammed to
pluripotency by fusion with ESCs (heterokaryon) or by transgenic
induction of Oct4, Sox2, Klf4 and c-Myc (iPS).
the overexpression of C/EBPα [25] (Figure 2). This cellu-
lar conversion has been considered a transdifferentiation
event since it is irreversible and does not require the
retrodifferentiation of pre-B cells to previous progenitor
stages [81]. Using the cellular system generated in Graf ’s
laboratory, Radrı́guez-Ubreva and colleagues performed a
high-throughput methylation analysis to study changes in
DNA methylation during the transdifferentiation of pre-B
cells into macrophages [82]. Surprisingly, they did not find
any significant changes in DNA methylation during cellular
conversion. However, they were able to identify the expected
histone modifications in the genes that had previously been
described to be upregulated or downregulated during the
process. In particular, they reported an increase in the
enrichment of the active histone marks H3K9/K14ac and
H3K4me3, at the promoters of upregulated macrophage-
specific genes, whereas a reduction of these modifications
was observed in the B-cell-specific downregulated genes. In
contrast, the repressive mark H3K27me3 was found to be
enriched in the B cell downregulated genes and reduced in
the upregulated macrophage-specific genes [82] (Figure 2).
This study suggests that histone regulators are able to
overcome the repressive effect of DNA methylation in
Comparative and Functional Genomics 7
macrophage-specific genes in the converted cells. It also
establishes an important difference from the process of
reprogramming towards pluripotency in which promoter
DNA demethylation plays a crucial role.
In this regard, Hanna and colleagues demonstrated
that pro-B and pre-B cells can be reprogrammed into
induced pluripotent stem (iPS) cells by the expression of
the transcription factors Oct4, Sox2, Klf4, and c-Myc [27].
Interestingly, the expression of the four factors in mature
B cells does not result in the reprogramming of mature B
cells to pluripotency. They found that expression of c/EBPα
in conjunction with the four “reprogramming” factors is
necessary to generate iPS cells [27] (Figure 2). iPS cell
lines derived from immature and mature B cells show
promoter demethylation of the stem cell markers Oct4 and
Nanog, whereas both promoters are heavily methylated in
the original B cells. Finally, in mature B cells the promoter
region of Pax5 shows high and low levels of enrichment
for the active mark H3K4me3 and the repressive mark
H3K27me3, respectively. Conversely, equivalent enrichment
of both histone modifications was observed in iPS lines
derived from mature B cells [27]. This study raises the
challenging question of how B lymphocytes at different
developmental stages differ in their epigenetic landscape
and how one factor can overcome this divergence to allow
reprogramming into pluripotent cells.
A number of studies using experimental heterokaryons,
in which a somatic cell is reprogrammed towards pluripo-
tency by fusion with mouse embryonic stem (ES) cells,
have also been used to reprogram B lymphocytes into
pluripotent cells. The laboratory of Amanda Fisher has
shown that when mouse ES cells are fused with human B
lymphocytes the expression of human pluripotent-associated
genes is rapidly induced [83]. Recently, the same group has
elucidated some of the epigenetic mechanisms underlying
this reprogramming process. They showed that deletion of
Eed, Suz12, Ezh2, and Ring1A/B, which are members of
either the polycomb repressor complex PRC1 or PRC2, in
mouse ES cells abolishes their capacity to induce human
B lymphocyte reprogramming towards pluripotency [84]
(Figure 2).
7. Concluding Remarks
The impressive advances in genome-wide methods and the
latest generation of ultrasequencing techniques are opening
up new, and challenging lines of research focused on the
elucidation of the epigenetic mechanisms underlying B cell
differentiation and reprogramming. Many questions remain
to be answered. Is there a specific “epigenetic signature” for
the different cellular states comprising B cell development?
How can lymphoid-specific transcription factors orchestrate
the epigenetic machinery at different genes and genome
regions to facilitate the choice to differentiate into a particu-
lar cellular lineage? Is the expression of epigenetic regulators
lineage-specific? Epigenetic modification analyses, genome-
wide RNA and ChIP-Seq studies, quantitative proteomics,
and systematic functional studies offer us the opportunity
to obtain high-quality measurements that will provide us
with a draft of the “epigenetic-transcriptional” program that
controls B cell development and reprogramming. Finally,
conditional gene inactivation in mice will reveal the role
of specific epigenetic regulators during B cell development.
Thus, new regulatory networks connecting epigenetic and
transcription factors seem likely to be revealed in the context
of B lymphopoiesis in the future.
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